BACKGROUND: Almost all newborns in the US are screened at birth for multiple inborn errors of metabolism using tandem mass spectrometry. Screening tests are designed to be sufficiently sensitive so that cases are not missed. The NACB recognized a need for standard guidelines for laboratory confirmation of a positive newborn screen such that all babies would benefit from equal and optimal follow-up by confirmatory testing.
The criteria routinely cited to justify screening newborns for inherited metabolic conditions include the availability of an ethical, safe, simple, and sensitive test to detect all cases (1 ) . Newborn screening panels have been limited by this constraint for nearly 40 years, since the advent of testing for phenylketonuria (PKU) 8 in dried blood spots (2, 3 ) . In the past decade, methods based on tandem mass spectrometry (MS/MS) have revolutionized the practice of newborn screening. In 2000, 100% of US newborns that were screened were tested for fewer than 10 conditions. Today, nearly all of the 4.3 million newborns in the US are screened for more than 30 conditions (4 ). Individually, these conditions are quite rare, but the collective inci-dence of disorders of amino, organic, and fatty acid metabolism detectable by MS/MS is approximately 1 in 4000 births (5 ) .
The body of literature dedicated to inborn genetic errors is extensive. The Online Database of Mendelian Inheritance in Man listed nearly 20 000 entries when accessed March 2, 2009 . The majority of knowledge regarding diagnosis and natural history of these disorders has been derived after the onset of symptoms. The presenting features of most inborn metabolic diseases are nonspecific and include lethargy, vomiting, characteristic odors, acidosis, and global developmental delay. Some of these disorders, such as PKU and maple syrup urine disease (MSUD), have a variable or slow progressive course and can result in profound neurologic damage before clinical diagnosis and treatment.
Other disorders, such as methylmalonic acidemia, glutaric acidemia type I, and fatty acid oxidation defects, may present acutely with life-threatening acidosis, hypoglycemia, seizures, and/or encephalopathy, with the presenting episode being the first chance to identify the disorder.
Although newborn screening presents the opportunity to diagnose and treat these disorders with unprecedented effectiveness, it presents the biochemical genetics laboratory with a challenge: to detect a disease state based primarily on a pattern of metabolic alterations often in the absence of characteristic clinical symptoms and physical signs of the disorder. After a positive newborn screen, the 3 most common tools available for follow-up testing are organic acid analysis in urine and analysis of amino acids and acylcarnitines in plasma or serum. A subset of these tests is normally required to confirm diagnosis. Because these are technically demanding procedures with considerable interlaboratory variability, the recommendations laid out in these guidelines are designed to standardize both the selection and practice of these procedures.
Toward this end, the National Academy of Clinical Biochemistry convened a panel of experts in metabolic genetic disorders and their associated complex laboratory methods to examine available peer-reviewed evidence and formulate principles for follow-up testing. The guidelines are based on the examination and interpretation of this evidence as well as the experience and opinion of the experts assembled to examine it. The panel graded the supporting data for each recommendation using criteria adopted from the US Preventive Services Task Force (see below) (6 ) . The document, revised after a public comment period, is divided into 5 sections. The complete guidelines are available at http://www.aacc.org/ members/nacb/lmpg/onlineguide/publishedguidelines/ newborn/pages/default.aspx. First, the evidence for expanded screening is reviewed (Chapter 1) followed by recommendations for analytic performance (Chapter 2) and selection of tests (Chapter 3) to be applied in the case of positive screening results. The final 2 sections outline the available evidence for improved outcomes (Chapter 4) and future directions in newborn screening (Chapter 5). Although adoption of these recommendations is voluntary, we hope that wide dissemination and adoption will improve the accuracy and efficiency of the process used to confirm metabolic disorders detected by expanded newborn screening programs using tandem mass spectrometry.
Strength of Recommendations (Modified from US Preventive Services Task Force's "Recommendations for Preventive Services")
A: The NACB strongly recommends adoption; there is good evidence that it improves important health outcomes, and the NACB concludes that benefits substantially outweigh harms. B: The NACB recommends adoption; there is at least fair evidence that it improves important health outcomes, and the NACB concludes that benefits outweigh harms. C: The NACB recommends against adoption; there is evidence that it is ineffective or that harms outweigh benefits. I: The NACB concludes that the evidence is insufficient to make recommendations; evidence that it is effective is lacking, of poor quality, or conflicting and the balance of benefits and harms cannot be determined.
NACB grades the quality of the overall evidence on a 3-point scale:
I: Evidence includes consistent results from welldesigned, well-conducted studies in representative populations. II: Evidence is sufficient to determine effects, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence. III: Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information.
Chapter 1: Evidence-Based Rationale for Expanded Newborn Screening
Among the traditional criteria cited and used to justify screening for a specific disorder are (1) the disease is detectable in the neonatal period before appearance of clinical symptoms; (2) As previously mentioned, the 3 basic tools for confirmatory testing are analyses of amino acids, organic acids, and carnitine esters. Each of these analyses is technically demanding and performed primarily in tertiary referral centers. Many of the recommendations are applicable to all 3 techniques and are an integral component of the best analytic laboratory practices associated with multianalyte profiles ( Table 2 ). Examples of these recommendations include analysis of normal and abnormal quality control specimens (A-I), subscription to proficiency testing programs when available (A-I), establishment of age-specific reference intervals (A-I), and identification of interfering substances (A-I). Each profile should be interpreted in the context of clinical history, physical symptoms, and other laboratory studies by a board-certified doctoral scientist or physician with specialized training in metabolic disease and pertinent analytic testing (A-I). Ideally, follow-up analyses should be performed within 24 h of sample receipt (A-I). Further recommendations specific to amino acid, organic acid, or acylcarnitine profiles are detailed below. Only the strongest recommendations are cited here.
AMINO ACID ANALYSIS
• Heparinized plasma from fasting patients is the preferred specimen type because it can be processed immediately. Serum is an acceptable alternative but not ideal. The extended time required for clot formation at room temperature may lead to artifacts such as glutamine deamination and oxidation of thiolcontaining amino acids. Cerebrospinal fluid (CSF) free of blood contamination is useful for investigating some seizure disorders (nonketotic hyperglycinemia), but such disorders are not effectively identified by screening programs. Likewise, urine amino acid analysis is useful as a first-line investigation in a few conditions (e.g., cystinuria) that are generally not detected in expanded screening programs.
• The specimen should be deproteinized before analysis. Sulfosalicylic acid is commonly used for ionexchange techniques, and methanol is normally used to extract free amino acids for analysis by mass spectrometry. Further sample cleanup may be performed but is not normally necessary.
• Ion-exchange techniques should use a retention time internal standard (e.g., aminoethylcystine) and derivatization for identification and quantification. Derivatization using o-phthalaldehyde, phenylisothiocyanate, and ninhydrin may be used. Postcolumn detection with ninhydrin provides consistent results and is used most commonly. Ninhydrin derivatives may be further analyzed at 2 wavelengths (e.g., 570 and 440 nm) to assess peak purity. Calibration is performed with a series of external standards.
• Derivatization, specifically butylation, is recommended for MS/MS analyses to enhance ionization and analytic specificity.
• Chromatography is required for MS/MS techniques to separate key isobaric constituents (e.g., alloisoleucine, isoleucine, leucine, and hydroxyproline).
ACYLCARNITINE ANALYSIS
• Following the rationale given above for amino acid analysis, plasma is the preferred specimen type for acylcarnitine analysis.
• The sample matrix should be simplified by solidphase or liquid-liquid extraction. Methanol extraction is most commonly used. • Chemical derivatization is recommended to enhance analytic sensitivity and molecular specificity. Vast analytic experience and expertise exist for the measurement of acylcarnitine butyl esters.
• Carnitine esters should be analyzed by electrospray ionization tandem mass spectrometry in either multiple reaction monitoring (MRM) or precursor ion scanning mode, or both. Chromatographic separation of isobaric carnitine esters is not normally required during initial follow-up studies. In the presence of interfering substances (e.g., pivalic acid, cefotaxime), chromatographic separation of acylcarnitines or use of other complementary techniques such as urine organic acid analysis may be necessary to augment diagnostic information.
• Pure forms of the Ͼ30 carnitine esters measured are not available, and full external calibration is not possible. Quantification should be accomplished by calculating the signal intensity of a specific ester to that of an appropriate deuterated internal standard. Quantification of carnitine esters that lack identical internal standards should be performed by using the ester with the internal standard with the nearest appropriate chain length (e.g., quantifying C16:1 with deuterated C16). Linearity, imprecision, and limits of detection must be frequently validated under the conditions used.
ORGANIC ACID ANALYSIS
• Urine is the specimen of choice. Random urine collections are acceptable. Diagnostic organic acids are concentrated in urine, making detection easier in this matrix as opposed to blood or CSF.
• Analysis should be normalized to urine creatinine concentration.
• Organic acids should be isolated from the matrix by extraction and derivatized before analysis. Ethyl acetate extraction and formation of trimethylsilyl derivatives are the most common strategies.
• Organic acids should be analyzed by capillary GC-MS.
• Analysis may be performed quantitatively or semiquantitatively. Abundant molecular species may be detected by a full ion scan from m/z 50 to 550. Selected ion monitoring (SIM) should be used to increase the sensitivity of detecting less abundant but clinically important molecular species (e.g., 3-hydroxyglutaric and 4-hydroxybutryic acids). A migration toward quantitative methods that increasingly rely on stable isotopes will improve the detection of subtle metabolic abnormalities and reduce laboratory-to-laboratory variability in organic acid measurement.
• Organic acids should be identified by retention time and mass spectra. Many diagnostically important compounds must be distinguished from coeluting organic acids (e.g., ethylmalonic/phosphoric acid, 3-hydroxybutyric/3-hydoxyisobutyric acid, and 2-ketoglutaric/3-hydroxyglutaric acid).
Chapter 3: Follow-Up of Positive Screens
Before expanded newborn screening, biochemical investigations were normally prompted by a multitude of nonspecific symptoms, including vomiting, lethargy, tachypnea, seizures, and encephalopathy. In symptomatic patients, biochemical abnormalities are not often subtle. Diagnostic metabolites may be present at concentrations an order of magnitude greater than those found in normal, age-matched children. In contrast, biochemical studies prompted by abnormal newborn screening results are not accompanied by clear-cut symptoms. In fact, most infants are asymptomatic at the time of sampling. Consequently, laboratory tech- 
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Special Report niques used for follow-up studies must be able to detect more subtle metabolic abnormalities. Because the rarity of these conditions precludes large studies of diagnostic accuracy, we examined primary literature summarizing studies in asymptomatic individuals as well as accumulated follow-up data. This exercise yielded general recommendations for the follow-up process ( Fig.  1) as well as specific follow-up test menus tailored to specific abnormal newborn screening results ( Table 3) . The laboratory is central to the follow-up process. Laboratory personnel should be among the first notified of the impending referral of a screen-positive patient to arrange for test selection, prompt testing, or sample referral (A-I). The initial techniques used should serve 2 purposes: (1) to confirm the presence of a biochemical abnormality and (2) to identify the metabolic defect with enough precision to allow imple- 
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Special Report mentation of appropriate therapy. Interpretation of analytic results must distinguish pathologic alterations from changes in metabolite concentrations associated with maturation of organ systems, prematurity, diet, and other concurrent illnesses. Finally, the laboratory plays a dual role in closing the follow-up loop. First, results of follow-up testing are provided to newborn screening collaboratives to maintain sensitivity of the screening process while minimizing the false-positive rate. Second, laboratory personnel should be aware of newborn screening statistics such as local incidence and recall rate to provide optimal feedback to clinicians involved in the follow-up process. Many aspects of the follow-up process are illustrated by neonates who have increased blood propionylcarnitine concentrations. Elevations of propionylcarnitine (C3) may indicate deficiency of propionyl CoA carboxylase, holocarboxylase synthetase, methylmalonyl CoA mutase, cobalamin metabolism, or dietary cobalamin. Expert opinion and peer-reviewed data (11-15 ) strongly support (A-I) a follow-up protocol that includes a plasma acylcarnitine analysis along with urine organic acid analysis and serum cobalamin concentration to discriminate accurately among these possibilities and enable institution of proper acute therapy. Amino acid analyses do not contribute to clarifying the initial differential diagnosis but do play a chronic therapeutic role if the eventual diagnosis dictates protein/amino acid restriction. Table 3 includes an itemized list of disorders included in the ACMG panel, screening markers suggestive of disease, recommended follow-up analyses and informative metabolites used to confirm or exclude the diagnosis, and the level of evidence supporting the recommended protocol.
Chapter 4: Patient Outcomes from Expanded Newborn Screening
The ability of tandem mass spectrometry to detect multiple diagnostic markers in a single analytic run has greatly expanded the number of conditions detectable in newborns. The ability to detect these disorders is not, however, the ultimate goal of newborn screening programs. Rather, reduction of morbidity and mortality from the disorder is the aim. Effective treatment, a mild reversible phenotype, and a sufficient latent period before full development of the disease phenotype bode well for positive patient outcomes. Some fatty acid oxidation disorders, biotinidase deficiency, and 3-methylcrotonyl CoA carboxylase deficiency are examples of these "milder" disorders. On the other hand, propionic acidemia, methylmalonic acidemia, and type II glutaric aciduria often present catastrophically before results of newborn screening analyses are available. Improving outcomes in these situations is more challenging. Outcome assessment is complicated by the rarity of these disorders, lack of standardized care, and the variability of the expression of the same enzymatic defect in different patients. We assessed outcomes of expanded newborn screening in this context. The results of this outcome analysis are presented in Table 4 . Given the relative infancy of expanded newborn screening it is not surprising that evidence supports screening for only a very few conditions; these include medium-chain acyl-CoA dehydrogenase (24 -27 ) , as well as propionic, methylmalonic, and isovaleric acidemias (A-II) (28 ) . Other conditions suffer from a variety of gaps in the amount or quality of evidence and carry weaker recommendations. These gaps include small numbers of affected patients (e.g., medium-/short-chain hydroxyacyl CoA dehydrogenase deficiency), very mild, ill-defined phenotypes (e.g., short-chain acyl CoA dehydrogenase deficiency), poor screening accuracy (e.g., tyrosinemia type 1), and lack of treatment options (e.g., glutaric aciduria type II).
On the positive side, the state of this evidence is dynamic and continues to accumulate. Pooling of data from worldwide programs and thoughtful analysis in terms of screening cutoffs, treatment approaches, and their clinical impact will allow periodic reassessment of the efficacy of screening. Hasty conclusions regarding inclusion or removal of markers for specific conditions are not appropriate in the ever-changing screening environment, since development of screening markers and treatments need not be synchronous. Should efforts to detect serious disorders (e.g., lysosomal storage diseases) stop because effective treatment does not currently exist? Should some apparently minor conditions (e.g., short-chain acyl-CoA dehydrogenase deficiency) be excluded from screening because our current experience indicates that these disorders have almost no discernible phenotype? Such disorders may be important modifiers of other disease processes as children age and therefore should be preserved pending thorough longitudinal evaluation of adequate numbers of such patients.
Chapter 5: Future Directions in Expanded Newborn Screening for Metabolic Disorders
Newborn screening programs will certainly continue to evolve, with tandem mass spectrometry as the basis for expansion. Development of effective disease markers detectable in blood spots by mass spectrometry lowers or removes the "ease of detection" hurdle for many disorders and will enable prospective evaluation of treatments and eventual outcomes for these disorders. New markers and new analytic methods beyond the measurement of amino acids and acylcarnitines are already driving this evolution. Assessment of enzyme activity, steroids, organic acids, and bile acids promise to enhance the scope of disease detection.
The most immediate group of disorders under consideration for widespread screening is the lysosomal storage diseases (LSDs). These disorders were lowpriority targets in the ACMG expert panel, in part because detection was not considered feasible, costeffective, and simple (7 ). However, enzyme activities specific for these storage diseases are stable in blood spots and can be assessed using appropriate synthetic substrates and tandem mass spectrometry (29 -31 ) . At the same time, enzyme replacement therapy for a number of these conditions is available or is in development. Such therapy has demonstrated some efficacy in patients with well-established disease but lacks impact on the central nervous system manifestations that most of these disorders produce (32) (33) (34) (35) . Early detection in concert with new therapies now provide an opportunity to investigate the potential of early enzyme replacement on disease progression. Currently, only the state of New York in the US has implemented population screening of a single LSD, Krabbe disease. Recommendations for implementation of LSD screening must await the outcome of these early trials.
Tyrosinemia type 1 represents the converse of the current status of LSDs. Although effective treatment exists, the measurement of blood spot tyrosine does not effectively discriminate affected neonates from normal ones. The pathognomonic metabolite of tyrosinemia type 1 is succinylacetone, rather than tyrosine. Methods to detect succinylacetone in dried blood spots under analytic conditions comparable to those for amino acids and acylcarnitines have recently been developed to circumvent this issue (36, 37 ) . This approach has been implemented in some laboratories to reduce false-positive screening rates, but proof from prospective screening of large populations is still lacking.
Tandem mass spectrometry promises to be a universal platform for identifying inborn errors detectable using not only small molecules, but also proteins. The expanding menu of small molecules also includes steroids for detection of congenital adrenal hyperplasia (38, 39 ) , bile acids for identifying hepatobiliary diseases (40 ) , and creatine and guanadinoacetate for diagnosing creatine synthetic and transport disorders (41, 42 ) . Feasibility of detecting larger molecules has also been demonstrated. Peptides derived from ceruloplasmin may enable diagnosis of Wilson disease in dried blood spots (43 ) . These additional analytic approaches based on MS/MS would require little new equipment and allow cost-effective expansion of conditions detectable in newborn screening programs. Evidence is currently incomplete, but accumulating. 
